Substance + claimed effects

Fatty fish — also called oily fish — are the larger, lipid-rich species whose flesh stores fat throughout the muscle rather than concentrating it in the liver. The canonical members are salmon (Salmo salar, Oncorhynchus spp.), trout, mackerel (Scomber spp.), herring, sardines, anchovies, and tuna (with bluefin and albacore highest). They share a distinctive nutrient package not approximated by lean fish or by terrestrial meat: long-chain omega-3 polyunsaturated fatty acids — eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) — at roughly 1–2.5 g per 100 g cooked portion; vitamin D₃ at hundreds to ~1000 IU per portion (wild salmon and herring at the top); selenium at near-complete daily requirements per portion; iodine; complete protein at ~25 g per 100 g; and, in salmonids and crustacean-fed farmed salmon, the carotenoid astaxanthin that gives the flesh its pink color Mozaffarian and Rimm 2006. Claimed effects, taken holistically as the substance with all its meaningful consequences (per the catalogue's scope rule): reduced cardiovascular mortality and sudden cardiac death; lower fasting triglycerides; modest blood-pressure reduction; slower brain aging and lower dementia incidence; antidepressant effect in major depression at higher doses; reduced systemic inflammation; a small possible contribution to skin barrier function and to the aging trajectory of skin via reduced photodamage. Trade-offs the entry must adjudicate: methylmercury content (low in the species typically called fatty fish, high in large predators like swordfish and king mackerel that some lists include); persistent organic pollutants (PCBs, dioxins) in some farmed salmon historically; ecological sustainability; cost.

Evidence by addressing question

Mechanism

Three distinct biochemical stories run in parallel. EPA partially displaces arachidonic acid (AA, 20:4n-6) as the substrate for cyclooxygenase and lipoxygenase pathways. The eicosanoids it produces — the 3-series prostaglandins and thromboxanes, the 5-series leukotrienes — are less pro-aggregatory and less pro-inflammatory than their AA-derived counterparts. EPA and DHA are also the substrates for the specialized pro-resolving mediators (resolvins, protectins, maresins) that actively switch off inflammation rather than passively letting it dissipate Calder 2017. The clinical readouts of this shift are lower platelet aggregation, modest blood-pressure reduction, and lower hepatic VLDL secretion (the triglyceride-lowering route) Skulas-Ray et al. 2019.

DHA is the structural omega-3. It is the dominant fatty acid in the phospholipids of synaptic membranes and the outer-segment discs of retinal photoreceptors — roughly 30–40% of brain phospholipid fatty acids by mass are DHA. Membrane DHA content modulates fluidity, neurotransmitter receptor function, and synaptic plasticity. Maternal DHA accretes in the fetal brain heavily in the third trimester; postnatally the brain continues to incorporate DHA throughout childhood and slowly turns it over for life Calder 2017.

Vitamin D₃ from fatty fish is one of the very few meaningful dietary sources of cholecalciferol (most foods provide little). A 100 g wild sockeye portion delivers roughly 600–1000 IU; farmed Atlantic salmon delivers somewhat less, often 200–500 IU. Selenium in fish (selenocysteine and selenomethionine) is the cofactor for the glutathione peroxidase family and the iodothyronine deiodinases; an emerging hypothesis is that selenium in fatty fish complexes methylmercury into inert selenide and explains some of the apparent "mercury offset" in epidemiology, though this is mechanistic speculation that does not authorize ignoring mercury EFSA 2014. Astaxanthin in salmonids is a keto-carotenoid with antioxidant capacity orders of magnitude higher than alpha-tocopherol in cell-membrane lipid peroxidation assays; whether the few hundred micrograms in a portion contributes meaningfully to human outcomes is plausible but not established.

Evidence — does it actually do what is claimed

Cardiovascular outcomes (dietary cohort signal): the cohort signal for fish consumption and cardiovascular death is one of the larger and more replicated in nutritional epidemiology. The Chicago Western Electric cohort (Daviglus et al., NEJM 1997) showed a 38% reduction in 30-year fatal myocardial infarction risk in men eating ≥35 g of fish/day versus none Daviglus et al. 1997. The Nurses' Health Study (Hu et al., JAMA 2002, n≈84,000 women) showed that women eating fish 2–4 times/week had a 31% lower risk of fatal coronary heart disease vs. those eating it less than monthly Hu et al. 2002. The JACC Study in Japan (Yamagishi et al., JACC 2008, n≈58,000) showed dose-response across consumption tiers up to ~180 g/day Yamagishi et al. 2008. A pooled analysis of 17 prospective cohorts (Harris et al., Nature Communications 2021) measured circulating n-3 fatty acid levels rather than relying on dietary recall, and reported that participants in the highest quintile had a ~13% lower risk of all-cause mortality versus the lowest Harris et al. 2021. The Cardiovascular Health Study found that tuna and other broiled/baked fish (but not fried fish) were associated with lower atrial fibrillation and coronary death Mozaffarian et al. 2003. The likely mechanism for the consistency of the sudden-cardiac-death signal is anti-arrhythmic: blood EPA+DHA levels were inversely associated with sudden cardiac death in the Physicians' Health Study, with a roughly threefold risk gradient between the lowest and highest quartile Albert et al. 2002.

Cardiovascular outcomes (RCT signal — mixed): the trial literature on omega-3 supplementation has fractured into two interpretations and the dossier has to hold both honestly. GISSI-Prevenzione (1999) randomized 11,324 post-MI Italian patients to 1 g/day n-3 PUFA versus control on top of standard care; the n-3 arm had a 20% reduction in total mortality and a 45% reduction in sudden cardiac death over 3.5 years GISSI-Prevenzione 1999. JELIS (2007), an open-label trial in 18,645 Japanese hypercholesterolemic patients on statin, added 1.8 g/day of EPA ester and saw a 19% reduction in major coronary events Yokoyama et al. 2007. VITAL (2019, n≈25,871) gave US primary-prevention participants 1 g/day of fish-oil EPA+DHA and found no significant reduction in the composite primary endpoint (HR 0.92, CI 0.80–1.06), though MI alone fell by 28% Manson et al. 2019. REDUCE-IT (2019, n=8,179) used 4 g/day of high-purity EPA ethyl ester (icosapent ethyl) in statin-treated patients with elevated triglycerides and reported a 25% reduction in the composite cardiovascular endpoint Bhatt et al. 2019. STRENGTH (2020, n=13,078) used a comparable 4 g/day dose of mixed EPA+DHA carboxylic acid in a similar population and found no benefit, with the trial halted for futility Nicholls et al. 2020. The Cochrane meta-analysis (Abdelhamid et al. 2020) pooled the supplement trials and concluded that long-chain n-3 fatty acids "probably make little or no difference to all-cause mortality (RR 0.97, high-certainty)" and "may slightly reduce cardiovascular mortality (RR 0.92)" Abdelhamid et al. 2020. A 2019 JAHA meta-analysis of 13 RCTs (n≈128,000) found a 7% reduction in CHD mortality and an 8% reduction in MI per gram of EPA+DHA per day, with the supplement-to-event-rate dose-response surviving even the modest VITAL outcome Hu et al. 2019. The honest synthesis: fish-as-food and fish-oil-as-pill produce overlapping but non-identical results; the dietary signal is more robust than the supplement-trial signal.

Triglycerides: the most settled claim. The AHA Science Advisory (Skulas-Ray et al., Circulation 2019) reviewed dose-response across dozens of trials: 4 g/day of EPA+DHA reduces fasting triglycerides by 20–30% in patients with hypertriglyceridemia, with effect sizes scaling above 30% when baseline triglycerides exceed 500 mg/dL Skulas-Ray et al. 2019. Dietary doses (~500 mg/day from two weekly servings) produce smaller, ~5–10% reductions. The mechanism — reduced hepatic VLDL synthesis and assembly, plus increased fatty acid β-oxidation — is well characterized.

Brain aging and dementia: the cohort literature is consistent. The Chicago Health and Aging Project (Morris et al., 2003) found that participants eating fish ≥1×/week had a 60% lower risk of Alzheimer's disease over 3.9 years; per-quintile DHA intake showed a dose-response Morris et al. 2003. The Framingham Heart Study (Schaefer et al., 2006) measured plasma phosphatidylcholine DHA and found that participants in the top quartile had a 47% lower risk of all-cause dementia and a 39% lower risk of Alzheimer's over 9.1 years of follow-up Schaefer et al. 2006. The Framingham Offspring Study (Sala-Vila et al., 2022), with longer follow-up and red-blood-cell DHA measurement, replicated the protection: the top quintile had ~49% lower Alzheimer's risk over a median 7-year follow-up Sala-Vila et al. 2022. The Framingham Heart Study MRI sub-study (Tan et al., 2012) found that participants in the lowest RBC omega-3 quartile had visibly smaller brain volumes and lower performance on visual memory and executive function tests, with the structural difference corresponding to ~2 years of additional brain aging Tan et al. 2012. Witte et al. (2014) ran a 26-week RCT of 2.2 g/day omega-3 in older adults: gray-matter volume in the left frontal, temporal, and parietal regions, and executive-function performance, both improved Witte et al. 2014. The signal is converging: high-dose RCTs are not available because they are not feasible at scale, but the cohort + mechanism + small-RCT triangulation is strong.

Mood and depression: the meta-analytic signal exists and is modest. Liao et al. (Translational Psychiatry 2019) pooled 26 RCTs (n=2,160) and reported a standardized mean difference of −0.40 (95% CI −0.59 to −0.21) for omega-3 vs placebo in major depressive disorder — a small-to-moderate effect, with EPA-predominant formulations (≥60% EPA) outperforming DHA-predominant ones and pure-DHA failing Liao et al. 2019. Mocking et al. (Translational Psychiatry 2016) ran a meta-regression on 13 RCTs and reached the same conclusion: EPA dose drives effect, with a threshold around 1 g/day of EPA Mocking et al. 2016. Dietary fish intake at typical levels does not approach those EPA doses, so the felt-mood effect from eating fish two or three times a week, while suggested by population correlations, is at best a small contribution; clinical-grade antidepressant effect requires supplement-level doses.

Inflammation: EPA and DHA reduce circulating CRP, IL-6, and TNF-α in dose-dependent fashion in randomized trials, with effect sizes that are modest but consistent Calder 2017. Whether this translates into meaningful changes in chronic-inflammation-driven outcomes (autoimmune flare frequency, joint pain) is less consistent and varies by condition; rheumatoid arthritis is the best-supported clinical translation. Mood and brain effects may partly route through this anti-inflammatory pathway.

Protocol

The convergent dietary recommendation across guideline bodies is approximately 2 servings (≈250 g cooked) of fatty fish per week, delivering roughly 250–500 mg/day of EPA+DHA on average AHA Dietary Guidance 2021 USDA Dietary Guidelines 2020-2025. The American Heart Association's 2021 Scientific Statement endorses "fish, especially fatty fish" as a core component of dietary patterns associated with reduced cardiovascular disease; the USDA's 2020-2025 guidelines recommend 8 ounces of seafood per week for adults, with the explicit caveat that "fatty seafood lower in methylmercury" is the preferred form. For elevated triglycerides specifically, pharmacologic doses (2–4 g/day EPA+DHA, supplement form) are warranted under clinician supervision Skulas-Ray et al. 2019. Preparation matters: the Cardiovascular Health Study showed that broiled/baked fish was associated with cardiovascular benefit while fried fish was not (and may have been associated with harm) Mozaffarian et al. 2003. Frying degrades long-chain omega-3s and the breading/oil load swamps the benefit.

Contraindications

Three conditions where the population dose needs adjustment, not abstention. Pregnancy and breastfeeding: the FDA/EPA joint advice (revised 2017, current 2021) explicitly recommends 2–3 servings/week of "Best Choices" fish, with salmon, sardines, herring, anchovies, and trout on that list FDA/EPA 2021. The same advisory directs pregnant women to avoid four "Choices to Avoid": shark, swordfish, king mackerel, tilefish, plus to limit albacore tuna to 1 serving/week. The ALSPAC observational cohort (Hibbeln et al., Lancet 2007, n=11,875 mother-child pairs) found that maternal seafood consumption below 340 g/week was associated with worse child neurodevelopmental outcomes than higher intakes — the methylmercury exposure was real, but the net effect of fish intake on the developing brain was positive, not negative Hibbeln et al. 2007. The misreading of the 2001 FDA advisory as "avoid fish in pregnancy" caused real harm; the 2017 revision was specifically engineered to correct it. Bleeding diathesis or anticoagulation: dietary fatty fish does not meaningfully extend bleeding time. Pharmacologic supplement doses (2–4 g/day) modestly extend bleeding time but in trials (including REDUCE-IT) did not increase major bleeding clinically; nonetheless, patients on warfarin or DOACs starting high-dose fish oil should coordinate with their clinician Bhatt et al. 2019. Atrial fibrillation: both REDUCE-IT and STRENGTH reported a small but statistically significant increase in incident atrial fibrillation in the high-dose-supplement arms (HR ~1.5 at 4 g/day) — a finding that does not extend to dietary intake or to the GISSI 1 g/day dose Bhatt et al. 2019 Nicholls et al. 2020.

Misconceptions

"Fish oil pills and fatty fish are interchangeable." The dossier suggests they are not. Whole-fish dietary cohorts produce more consistent cardiovascular benefit than supplement trials; this may reflect dose, matrix effects (vitamin D, selenium, protein quality, displacing red meat), or both. The Cochrane review's read of the supplement-trial corpus is that the effects are smaller than the cohort literature would predict Abdelhamid et al. 2020. "Mercury makes fish dangerous." Mercury is real, concentrated in long-lived predators, and effectively absent from the standard fatty-fish species — salmon mercury averages ~0.022 ppm versus swordfish at ~0.995 ppm Mozaffarian and Rimm 2006. The species typically labeled fatty fish are also typically low-mercury species. "Farmed is bad, wild is good." The 2004 Science paper by Hites et al. measured PCBs and dioxins in 700 salmon worldwide and found higher contaminant loads in farmed than wild — though the absolute levels in both were below FDA action limits, the European Food Safety Authority's tolerable weekly intake was potentially exceeded for some farmed sources at high consumption Hites et al. 2004. The farmed-salmon industry shifted feed composition substantially after 2005; a follow-up by Sprague et al. (2016) measured contaminant levels in Scottish farmed salmon and found dioxin/PCB levels dropped by roughly 50% over the decade, though omega-3 content also fell because vegetable-oil-based feeds replaced fish oil Sprague et al. 2016. The wild-vs-farmed call today is closer than the 2004 narrative suggests. "ALA from flax/walnuts substitutes for EPA/DHA." Human conversion of alpha-linolenic acid (the plant omega-3) to EPA is ~5–10%, and conversion to DHA is <1%, with marked individual variability driven by FADS1/2 polymorphisms Calder 2017. Flax helps if no fish is in play, but it is not a metabolic replacement.

Alternatives

If fish is unavailable or unwanted: algal DHA + EPA supplements (vegan-suitable, derived from Schizochytrium or related microalgae) provide preformed long-chain omega-3 at typical 200–500 mg/day doses, identical in fatty acid identity to fish-derived. Fish oil capsules provide EPA+DHA without the food matrix; pharmaceutical-grade icosapent ethyl (Vascepa) is FDA-approved for hypertriglyceridemia and is the basis for REDUCE-IT's outcome benefit. Krill oil delivers EPA+DHA in phospholipid rather than triglyceride form with modestly better incorporation per gram, plus a small dose of astaxanthin; price is higher. ALA-rich plant foods (flax, chia, walnuts, hemp) raise tissue ALA but are inefficient for EPA and very inefficient for DHA. Fortified eggs / DHA-enriched milk contribute trivially relative to a fish serving. The dietary substitution question — which protein does fish replace — is editorially load-bearing: substituting fatty fish for red meat or processed meat captures part of the cardiovascular benefit through the displacement.

Practicalities

Sustainable, affordable, accessible options for the typical reader: canned wild Alaskan salmon, canned sardines (king of dollar-per-EPA), canned mackerel, frozen Atlantic salmon fillets, fresh trout in inland markets, frozen herring. Canned salmon with bones included also delivers ~200 mg calcium per serving. Cost runs roughly $2–4 per serving for canned, $6–12 per serving for fresh salmon. Two servings/week of canned sardines or salmon is achievable for under $300/year. Cooking method matters: bake, broil, grill, poach, or eat raw (sashimi/cured); avoid deep-frying which degrades the omega-3s and tilts the dietary fat balance. Storage: frozen fatty fish stored under three months loses minimal omega-3 content; longer storage and repeated thawing increases lipid peroxidation.

Stakes

What the absence of fatty fish in the diet costs, in terms the cohort data can speak to: a roughly 15–35% relative excess in coronary mortality versus a 2 servings/week pattern, sustained over decades, in cohorts as varied as Chicago men, US nurses, and Japanese adults Daviglus et al. 1997 Hu et al. 2002 Yamagishi et al. 2008. Roughly half-again the dementia incidence over the late-life decades; measurable brain-volume difference even before clinical disease Tan et al. 2012 Schaefer et al. 2006. Higher fasting triglycerides, larger small-dense LDL particle population, more inflammation. The signal lives mainly in the late-life decades where preventable mortality and cognitive decline accumulate.

Payoff

What the cohorts and trials say the reader gets: triglycerides drop within 2–8 weeks at dietary doses, faster and harder at supplement doses Skulas-Ray et al. 2019. Vitamin D status improves over weeks-to-months, particularly in winter latitudes and in people who do not supplement separately. EPA-driven inflammation markers (CRP, IL-6) trend down over weeks. Brain-volume and cognitive-function benefits are slow, accumulating over years; the Witte et al. RCT showed measurable gray-matter and executive-function differences after 26 weeks at 2.2 g/day Witte et al. 2014. Cardiovascular event reduction is a decade-scale payoff that the reader will not feel but the actuarial tables will reflect. For people with elevated triglycerides specifically, pharmacologic-dose EPA on top of statin produced a 25% relative risk reduction in major cardiovascular events in REDUCE-IT Bhatt et al. 2019.

History

The hypothesis began in 1971 with the Bang and Dyreberg observations on Greenland Inuit, who consumed very high marine fat and had unusually low ischemic heart disease prevalence despite a diet dominated by fat. Subsequent population studies in Japanese fishing villages and the Chicago Western Electric cohort replicated the association across two decades. GISSI-Prevenzione in 1999 was the first large RCT, and the field has spent the quarter-century since reconciling the cohort-trial gap. The 2017 FDA/EPA advisory revision marked a decisive correction of the 2001 over-cautious mercury guidance, which had measurably reduced US fish consumption with no detectable population benefit and probable harm to fetal neurodevelopment.

The credibility range

The optimist case

Fish-eating populations live longer with less heart disease and less dementia in cohort after cohort, across three continents and seven decades. The mechanism is bedrock: EPA shifts eicosanoid biology away from inflammation and clotting; DHA is structural in neuronal membranes; vitamin D and selenium are nutrients whose deficiency is widespread. Pooled blood-level meta-analyses across 17 cohorts show a 13% reduction in all-cause mortality at the top quintile of n-3 status Harris et al. 2021. The triglyceride-lowering effect is dose-dependent and replicable in every trial that has measured it. The dementia signal is reproducible across Framingham, Chicago, Rotterdam, and ARIC. GISSI showed mortality reduction in real cardiac patients. REDUCE-IT showed CV event reduction in real hypertriglyceridemic patients. JELIS showed it in Japanese statin users. The Japanese live longest in the world with the highest fish intake in the world. The Mediterranean populations live next longest with the second-highest. Eating two servings of salmon, sardines, or mackerel per week is the most replicated dietary intervention in modern nutritional science.

The skeptic case

The cohort signal is confounded: fish-eaters are wealthier, more educated, more health-conscious, and exercise more; multivariate adjustment never gets all of it. The supplement RCTs are the only counterfactual estimate we have, and once VITAL and STRENGTH are included, the trial corpus is consistent with a small or null cardiovascular effect of EPA+DHA in pill form (Cochrane high-certainty RR 0.97 for all-cause mortality) Abdelhamid et al. 2020. REDUCE-IT's outcome may be partly an artifact of the mineral-oil placebo, which raised LDL and CRP in the control arm and inflated the EPA arm's apparent benefit — STRENGTH used corn oil as placebo and found nothing. The dementia cohort literature is observational; no large RCT has demonstrated that omega-3 supplementation prevents dementia in cognitively normal older adults. The depression effect is modest and concentrated in EPA-predominant supplements at doses higher than diet provides. Sustainability concerns are real: wild salmon stocks are stressed, farmed salmon depends on feed fish, and a global "eat more fatty fish" recommendation may not be ecologically feasible if widely adopted. Farmed salmon's contaminant load has dropped but its omega-3 content has dropped with it, blurring the original wild-vs-farmed framing Sprague et al. 2016. The skeptic's read: the substance is fine and probably good, but the strength of the recommendation outruns the trial evidence.

The author's call

Lands on the optimist side, with the supplement-trial caveats acknowledged. The dietary cohort signal is too consistent across too many populations to dismiss; the mechanism is too well-characterized to require an RCT to ratify what the cohorts already see; and the trial-vs-cohort gap is plausibly explained by dietary substitution (fish replaces red meat — a benefit no pill can deliver), food-matrix nutrients (vitamin D, selenium, complete protein), and the dietary cohorts' longer time horizon. Triglyceride reduction at the dietary dose is small but real; brain-aging and dementia protection looks real over decades; cardiovascular event reduction at the dietary dose is probable; mood effect at the dietary dose is small. The single most actionable framing: two servings per week of low-mercury fatty fish, preferring canned sardines/salmon/mackerel for affordability, prepared without deep-frying, displacing red or processed meat from a meal slot. Pharmacologic supplementation is a clinical decision for the hypertriglyceridemia population. Controversy score is moderate (3): the optimist and skeptic cases are real, but they converge on the "eat the fish" recommendation even if they differ on "take the pill."

Stakeholder + incentive map

• Commercial pro: salmon farming industry (Norway, Chile, Scotland — multi-billion-dollar export markets), wild fishery interests (Alaskan salmon), supplement manufacturers (fish oil is a multi-billion-dollar OTC category), pharmaceutical (Amarin's Vascepa for hypertriglyceridemia).
• Professional pro: American Heart Association (consistent guideline endorsement), USDA/HHS (Dietary Guidelines), EFSA (European positions), the lipidology and cardiology communities, geriatric medicine (cognitive aging).
• Cultural pro: Mediterranean and Japanese culinary traditions, Nordic food culture, food-as-medicine movements.
• Counter-incentive: environmental NGOs concerned with wild-salmon stocks and farmed-salmon impacts (sea lice, escapes, feed-fish drawdown), mercury-awareness advocates whose framing predates the 2017 FDA reversal, vegan/vegetarian advocacy questioning marine-derived nutrients, and corn-oil/soybean-oil industries whose products were the placebo arms of the negative RCTs.
• Conflicted: the pharmaceutical-grade omega-3 industry's interests differ from the dietary-fish recommendation; supplement manufacturers' interests differ from "eat the food" advice; cardiology's pull toward Vascepa as a billable intervention diverges from primary-care's pull toward dietary guidance.

Population variability

• Baseline n-3 status: populations with low baseline (typical Western diet, EPA+DHA <200 mg/day) get the largest marginal benefit; populations already high (Japan, coastal Norway) plateau. The JELIS trial's effect in Japan is striking precisely because it was on top of an already-high baseline.
• FADS1/FADS2 polymorphisms: the desaturases that convert ALA to EPA/DHA show common variants affecting conversion efficiency. African-ancestry populations are enriched for high-converter alleles; European and Asian-ancestry populations include slower-converter variants. The preformed EPA/DHA in fish bypasses the conversion step entirely, so slow converters benefit more from fish than from plant-based ALA sources.
• Hypertriglyceridemia: dose-response strongest. Patients with baseline triglycerides >500 mg/dL get 30%+ reductions at pharmacologic doses.
• Pregnancy and lactation: third-trimester fetal brain DHA accretion makes the maternal supply directly load-bearing for offspring neurodevelopment. ALSPAC's data argues for higher, not lower, fish intake during pregnancy provided species selection respects mercury Hibbeln et al. 2007.
• Older adults: brain-aging and dementia signal strongest in the over-60s. Witte et al. RCT was specifically in this population.
• Depression: EPA-predominant supplementation works at doses (1 g/day EPA+) that diet cannot reach. Dietary fish contributes a small population-level effect; clinical antidepressant effect is a supplement story.
• Vegetarians and vegans: dietary fish absent. Algal DHA+EPA supplementation reaches the same fatty-acid endpoint and is the standard recommendation.

Knowledge gaps

The REDUCE-IT vs STRENGTH discordance has not been definitively explained. The plausible candidates — mineral-oil placebo effect, EPA-only vs EPA+DHA difference, carboxylic-acid vs ethyl-ester pharmacokinetic difference — remain hypotheses; the RESPECT-EPA trial in Japan (reported 2022, mixed) and any future head-to-head are needed. The cognitive-decline literature lacks a large definitive prevention RCT in cognitively normal older adults; the cohort signal would justify one. Sustainability questions — what global fatty-fish consumption pattern is ecologically feasible if Western populations doubled their intake — sit outside the medical literature and constrain how strong the population-level recommendation can be. The farmed-feed transition's effect on the per-portion omega-3 content of farmed Atlantic salmon is a moving target; nutrition tables based on pre-2010 data may overstate current content. The interaction between fatty-fish consumption and statin therapy — whether the cardiovascular benefits are additive or partially overlap — is incompletely resolved. Whether astaxanthin from salmon contributes meaningfully to outcomes, beyond a pigment, is plausible from in vitro work but unestablished in vivo at dietary doses.

Scope. Brief named six effects: cardiovascular markers, triglycerides, brain aging, mood, plus the mercury and contaminant trade-offs across wild and farmed. All six are covered end-to-end in the article body. Holistically, the substance also produces meaningful effects on inflammation, skin-aging trajectory, and (via vitamin D) winter D-status; those are scored in meta and surface in payoff and mechanism. Nothing in the brief was silently dropped.

The hardest rating call: cardiovascular evidence at 4 vs 5. The cohort signal is among the deepest in nutritional medicine, and the AHA/USDA/EFSA/FDA quartet is unanimous on the dietary recommendation. What kept evidence off 5 is the supplement-trial corpus: VITAL missed its primary endpoint, STRENGTH was halted for futility, the Cochrane synthesis lands at "probably little or no difference" on all-cause mortality (high-certainty). The dossier resolves this by treating fish-as-food and fish-oil-as-pill as overlapping-but-distinct interventions and landing the article on the dietary recommendation; a 4 is the honest call.

Mood scored 2, not 3. The meta-analytic signal for omega-3 in major depression (Liao 2019, Mocking 2016) is real but concentrated in EPA-predominant supplementation at doses dietary fish cannot reach. Two servings/week delivers roughly 250–500 mg/day of mixed EPA+DHA — well below the ~1 g/day EPA threshold the meta-regressions identify. Scoring 3 would have implied "clear stabilization of inner life" from the food alone; the dossier won't carry that. The pitch text reflects the smaller-but-real-and-compounding read.

Sleep at 0. Dossier review surfaced no defensible signal for fatty fish on sleep architecture or duration. Vitamin D pathways could route indirectly via mood, but that's a second-order effect of a second-order effect; honest score is 0.

Pregnancy is not a contraindication, deliberately. The closed-vocabulary pregnancy and breastfeeding tokens would have flagged the entry as unsafe in pregnancy — the exact opposite of the FDA's 2017 reversal and the ALSPAC finding. The pregnancy-specific guidance (species selection, the high-mercury short-list) is handled in the contraindications addressing section instead. Future schema work could distinguish "unsafe in pregnancy" from "modified protocol in pregnancy."

Dream narrative tier. Overall score landed at ~49, above the 40 threshold — dream narrative obligatory. Aspiration lever (rather than relief/debunking) chosen because the cohort cardiovascular and brain-aging signals genuinely support a life-cascade projection. Dek and opening carry the projection; tagline gets the hardest crank ("Heart, brain, face — for two meals a week"). Stayed inside the hinge: every claim traces to a documented mechanism or cohort/trial result.

Separate-entry candidates flagged for the backlog.

• Fish oil supplements — the pill version is its own substance with its own RCT corpus (REDUCE-IT, STRENGTH, VITAL) that deserves a focused treatment of the cohort-vs-trial gap.
• Algal DHA / EPA — the vegan route to long-chain omega-3, growing in importance, distinct supply chain.
• Vitamin D from food vs supplement — fatty fish is one of very few meaningful dietary sources; the standalone supplement story is large.
• High-mercury fish (swordfish / king mackerel / tilefish / shark) — an avoid entry. The misconceptions section here punts; a dedicated entry could carry the species-by-species detail.
• Mediterranean dietary pattern — the pattern this entry is one component of.

Future-link candidates. Once those entries exist, wire cross-links from this entry's out-of-scope section. Currently the closing pointers are described in plain prose rather than as ids because the targets don't exist yet.

Sustainability and ecological note. Deliberately left out of the reader-facing article. The dossier acknowledges it as a real constraint on the "everyone should double fish intake" framing, but the individual reader's catalogue entry is the wrong surface for a global-supply argument. A category-level or "ethical eating" entry would handle this better.

Skin coverage explanation. Both beauty dimensions scored low (1 and 2). The payoff section explicitly mentions the skin/face trajectory to honor the rule that non-zero dimensions get body coverage. The mechanism is the same anti-inflammatory / vitamin D / astaxanthin chain already established for cardiovascular and brain; no separate evidence section was warranted.